Update on denosumab in the management of postmenopausal osteoporosis: Patient preference and adherence

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions about the necessity of the prescribed medication to treat osteoporosis and the concerns about the potential adverse effects are important and potentially modifiable determinants of adherence, in addition to other factors, such as difficult dosing regimens and high dosing frequency. Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonvertebral, and hip fractures. It is administered subcutaneously every 6 months for the treatment of postmenopausal osteoporosis. Preference and adherence to Dmab treatment were assessed in various clinical trials. Although with some limitations, available data suggest that Dmab is preferred to bisphosphonates, produces greater satisfaction than bisphosphonates, and would be preferentially chosen for long-term treatment. Moreover, patient perceptions about the necessity of Dmab treatment clearly outweigh the concerns about the injections, and positive beliefs about treatment positively influence medication-taking behavior. According to these data, Dmab may represent a reasonable alternative to bisphosphonates, particularly for osteoporotic women in whom a suboptimal or even poor adherence to oral treatments is expected.

Original languageEnglish
Pages (from-to)833-839
Number of pages7
JournalInternational Journal of Women's Health
Volume7
DOIs
Publication statusPublished - Oct 13 2015

Fingerprint

Postmenopausal Osteoporosis
Patient Preference
Patient Compliance
Diphosphonates
Therapeutics
Osteoporosis
Hip Fractures
Osteoclasts
Bone Resorption
Cytoplasmic and Nuclear Receptors
Denosumab
Monoclonal Antibodies
Clinical Trials
Ligands
Injections

Keywords

  • Denosumab
  • Osteoporosis treatment
  • Preference
  • RANKL

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Maternity and Midwifery

Cite this

@article{7b26e5ce38284b2ca7c56127ac08fe34,
title = "Update on denosumab in the management of postmenopausal osteoporosis: Patient preference and adherence",
abstract = "Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions about the necessity of the prescribed medication to treat osteoporosis and the concerns about the potential adverse effects are important and potentially modifiable determinants of adherence, in addition to other factors, such as difficult dosing regimens and high dosing frequency. Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonvertebral, and hip fractures. It is administered subcutaneously every 6 months for the treatment of postmenopausal osteoporosis. Preference and adherence to Dmab treatment were assessed in various clinical trials. Although with some limitations, available data suggest that Dmab is preferred to bisphosphonates, produces greater satisfaction than bisphosphonates, and would be preferentially chosen for long-term treatment. Moreover, patient perceptions about the necessity of Dmab treatment clearly outweigh the concerns about the injections, and positive beliefs about treatment positively influence medication-taking behavior. According to these data, Dmab may represent a reasonable alternative to bisphosphonates, particularly for osteoporotic women in whom a suboptimal or even poor adherence to oral treatments is expected.",
keywords = "Denosumab, Osteoporosis treatment, Preference, RANKL",
author = "Elisa Cairoli and Cristina Eller-Vainicher and Iacopo Chiodini",
year = "2015",
month = "10",
day = "13",
doi = "10.2147/IJWH.S75681",
language = "English",
volume = "7",
pages = "833--839",
journal = "International Journal of Women's Health",
issn = "1179-1411",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Update on denosumab in the management of postmenopausal osteoporosis

T2 - Patient preference and adherence

AU - Cairoli, Elisa

AU - Eller-Vainicher, Cristina

AU - Chiodini, Iacopo

PY - 2015/10/13

Y1 - 2015/10/13

N2 - Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions about the necessity of the prescribed medication to treat osteoporosis and the concerns about the potential adverse effects are important and potentially modifiable determinants of adherence, in addition to other factors, such as difficult dosing regimens and high dosing frequency. Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonvertebral, and hip fractures. It is administered subcutaneously every 6 months for the treatment of postmenopausal osteoporosis. Preference and adherence to Dmab treatment were assessed in various clinical trials. Although with some limitations, available data suggest that Dmab is preferred to bisphosphonates, produces greater satisfaction than bisphosphonates, and would be preferentially chosen for long-term treatment. Moreover, patient perceptions about the necessity of Dmab treatment clearly outweigh the concerns about the injections, and positive beliefs about treatment positively influence medication-taking behavior. According to these data, Dmab may represent a reasonable alternative to bisphosphonates, particularly for osteoporotic women in whom a suboptimal or even poor adherence to oral treatments is expected.

AB - Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions about the necessity of the prescribed medication to treat osteoporosis and the concerns about the potential adverse effects are important and potentially modifiable determinants of adherence, in addition to other factors, such as difficult dosing regimens and high dosing frequency. Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonvertebral, and hip fractures. It is administered subcutaneously every 6 months for the treatment of postmenopausal osteoporosis. Preference and adherence to Dmab treatment were assessed in various clinical trials. Although with some limitations, available data suggest that Dmab is preferred to bisphosphonates, produces greater satisfaction than bisphosphonates, and would be preferentially chosen for long-term treatment. Moreover, patient perceptions about the necessity of Dmab treatment clearly outweigh the concerns about the injections, and positive beliefs about treatment positively influence medication-taking behavior. According to these data, Dmab may represent a reasonable alternative to bisphosphonates, particularly for osteoporotic women in whom a suboptimal or even poor adherence to oral treatments is expected.

KW - Denosumab

KW - Osteoporosis treatment

KW - Preference

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=84945183036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945183036&partnerID=8YFLogxK

U2 - 10.2147/IJWH.S75681

DO - 10.2147/IJWH.S75681

M3 - Article

AN - SCOPUS:84945183036

VL - 7

SP - 833

EP - 839

JO - International Journal of Women's Health

JF - International Journal of Women's Health

SN - 1179-1411

ER -